Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
BioMarin Pharmaceutical
BioMarin Pharmaceutical
Activities:
Distribution
Manufacturing
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Therapeutic: vosoritide for achondroplasia
Achondroplasia is the most common form of skeletal dysplasia, yet no effective therapies exist
Finance
Merck returns rights to metabolism drug Kuvan to BioMarin
Merck will receive an upfront payment of €340m plus €185m in additional milestones
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
New NCEs focus on cancer and orphan diseases
The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
Regulatory
Prosensa appoints Head of Global Regulatory Affairs
Dr Larry Bell will oversee global regulatory activities at the company
Regulatory
A lucrative niche in orphan diseases?
The number of potential blockbuster drugs is in decline so many Big Pharma companies are looking to rare diseases to fill their pipelines because low sales volumes can be balanced out by premium prices.
Regulatory
US FDA approves BioMarin plant expansion
Doubles current capacity at Novato, CA
Subscribe now